A phase 1/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndrome

A phase 1/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndrome

Abstract Invariant natural killer T (iNKT) cells, a unique T cell population, lend themselves for use as adoptive therapy due to diverse roles in orchestrating immune responses. Originally developed for use in cancer, agenT-797 is a donor-unrestricted allogeneic ex vivo expanded iNKT cell therapy. W...

Full description

Bibliographic Details
Main Authors: Terese C. Hammond, Marco A. Purbhoo, Sapana Kadel, Jerome Ritz, Sarah Nikiforow, Heather Daley, Kit Shaw, Koen van Besien, Alexandra Gomez-Arteaga, Don Stevens, Waldo Ortuzar, Xavier Michelet, Rachel Smith, Darrian Moskowitz, Reed Masakayan, Burcu Yigit, Shannon Boi, Kah Teong Soh, John Chamberland, Xin Song, Yu Qin, Ilya Mishchenko, Maurice Kirby, Valeriia Nasonenko, Alexa Buffa, Jennifer S. Buell, Dhan Chand, Marc van Dijk, Justin Stebbing, Mark A. Exley
Format: Article
Language:English
Published: Nature Portfolio 2024-02-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-024-44905-z

Internet

https://doi.org/10.1038/s41467-024-44905-z

Similar Items